Literature DB >> 22413806

Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.

Carole Evans1, David Cipolla, Tim Chesworth, Eva Agurell, Richard Ahrens, Dale Conner, Sanjeeva Dissanayake, Myrna Dolovich, William Doub, Anders Fuglsang, Afredo García Arieta, Michael Golden, Robert Hermann, Günther Hochhaus, Susan Holmes, Paul Lafferty, Svetlana Lyapustina, Parameswaran Nair, Dennis O'Connor, David Parkins, Ilse Peterson, Colin Reisner, Dennis Sandell, Gur Jai Pal Singh, Marjolein Weda, Patricia Watson.   

Abstract

The purpose of this article is to document the discussions at the 2010 European Workshop on Equivalence Determinations for Orally Inhaled Drugs for Local Action, cohosted by the International Society for Aerosols in Medicine (ISAM) and the International Pharmaceutical Consortium on Regulation and Science (IPAC-RS). The article summarizes current regulatory approaches in Europe, the United States, and Canada, and presents points of consensus as well as ongoing debate in the four major areas: in vitro testing, pharmacokinetic and pharmacodynamic studies, and device similarity. Specific issues in need of further research and discussion are also identified.

Mesh:

Substances:

Year:  2012        PMID: 22413806     DOI: 10.1089/jamp.2011.0968

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  17 in total

1.  A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

2.  Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.

Authors:  Benjamin Weber; Sau L Lee; Renishkumar Delvadia; Robert Lionberger; Bing V Li; Yi Tsong; Guenther Hochhaus
Journal:  AAPS J       Date:  2014-12-17       Impact factor: 4.009

Review 3.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

4.  Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.

Authors:  Sau L Lee; Bhawana Saluja; Alfredo García-Arieta; Gustavo Mendes Lima Santos; Ying Li; Sarah Lu; Shuguang Hou; Juliet Rebello; Abhijit Vaidya; Jaideep Gogtay; Shrinivas Purandare; Svetlana Lyapustina
Journal:  AAPS J       Date:  2015-05-23       Impact factor: 4.009

5.  Comparison of systemic pharmacodynamic effects of two combination pressurized metered dose inhalers that deliver salmeterol and fluticasone propionate.

Authors:  Lester I Harrison; Victoria Sessions; Christopher J Wiggenhorn; David Chalmers; Pui Leung; John Efthimiou
Journal:  Br J Clin Pharmacol       Date:  2017-08-01       Impact factor: 4.335

6.  A sensitivity analysis of the modified chi-square ratio statistic for equivalence testing of aerodynamic particle size distribution.

Authors:  Benjamin Weber; Sau L Lee; Robert Lionberger; Bing V Li; Yi Tsong; Guenther Hochhaus
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

Review 7.  Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.

Authors:  Ryosuke Kuribayashi; Toru Yamaguchi; Hanaka Sako; Tomoko Takishita; Kazunori Takagi
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

8.  A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics.

Authors:  David L Hava; Lisa Tan; Patrick Johnson; Aidan K Curran; Jason Perry; Steve Kramer; Katie Kane; Pauline Bedwell; Gary Layton; Clarie Swann; Dennis Henderson; Naimat Khan; Lucy Connor; Litza McKenzie; Dave Singh; James Roach
Journal:  Br J Clin Pharmacol       Date:  2020-01-16       Impact factor: 4.335

9.  Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler.

Authors:  Jason Perry; Brian Trautman; Joe Takher-Smith; Steve Kramer; Katie Kane; Michael Silverman; Lisa Tan; Scott Haughie; Wolfram Richter; Valentin Kirkov; Sacha Arsova; Jonathan Ward; David L Hava
Journal:  Br J Clin Pharmacol       Date:  2019-01-15       Impact factor: 4.335

10.  In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.

Authors:  Stephen T Horhota; Jan A van Noord; Cynthia B Verkleij; Loek J Bour; Ashish Sharma; Michael Trunk; Piet J G Cornelissen
Journal:  AAPS J       Date:  2015-03-21       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.